Previous issue | Volume 86 | ESPE2016 | Next issue

55th Annual ESPE

Paris, France
10 Sep 2016 - 12 Sep 2016

Card image cap
Paris, France: 10-12 September 2016 Further information

Poster Presentations

Growth P1

Somapacitan, a Once-Weekly Reversible Albumin-Binding Growth Hormone (GH) Derivative, Is Well Tolerated and Convenient in Adults with GH Deficiency (AGHD): Results from a 26-Week Randomised, Controlled Phase 3 Trial
aDepartment of Internal Medicine, University of Gothenburg, Göteborg, Sweden; bRigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; cGlobal Development, Novo Nordisk A/S, Søborg, Denmark; dMediCover Berlin-Mitte MVZ, Berlin, Germany; eService d’Endocrinologie-Diabétologie-Nutrition, Centre de référence des maladies rares de la réceptivité hormonale, CHU d’Angers, Angers, France; fDepartment of Neurosurgery, Nippon Medical School, Tokyo, Japan; gDepartment of Endocrinology, Queen Elizabeth Hospitals Birmingham, Birmingham, UK
hrp0086p1-p594
The Diagnostic Value of IGF-II, IGF-I and IGFBP-3 in Silver-Russell Syndrome
aUniversity Children’s Hospital, Pediatric Endocrinology, Tübingen, Germany, bInstitute of Human Genetics, RWTH Aachen, Aachen, Germany
hrp0086p1-p595
Functional in vitro Characterization of Two Novel Germinal STAT3 Mutations Associated with Short Stature, Immunodeficiency and Autoimmune Disease
aCentro de Investigaciones Endocrinológicas ‘Dr César Bergadá’ (CEDIE) CONICET – FEI – División de Endocrinología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina; bEndocrinología, Hospital Universitario Austral, Buenos Aires, Argentina; cInmunología, Hospital de Niños Ricardo Gutiérrez, Buenos Aires, Argentina; dDivision of Endocrinology, Cincinnati Center for Growth Disorders, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA; eInstituto de Agrobiotecnología de Rosario (INDEAR), CONICET, Rosario, Argentina; fDivision of BM transplantation and Immunodeficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, USA
hrp0086p1-p596
Abstract unavailable
hrp0086p1-p597
Human Phase1 Clinical Data of ALT-P1 (hGH-NexP) by Healthy Korean Males
aAlteogen Inc, Deajeon, Republic of Korea; bHan Nam University, Deajeon, Republic of Korea; cYonsei University, Seoul, Republic of Korea
hrp0086p1-p598
Validation of Prediction Models for Near Final Adult Height in Children with Idiopathic Growth Hormone Deficiency Treated with Growth Hormone for 1 Year
aMaastricht University Medical Center, Maastricht, The Netherlands; bThe Belgian Society for Pediatric Endocrinology and Diabetology, Brussels, Belgium; cUniveristy Hospital Brussels, Brussels, Belgium
hrp0086p1-p599
The Influence of Recombinant Human Growth Hormone Treatment on Very Small Embryonic/Epiblast Like Stem Cells
aDepartment of Pediatric in Krakow and Adolescent Endocrinology, Pediatric Institute, Medical College, Jagiellonian University, Cracow, Poland; bDepartment of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland; cStem Cell Institute at the James Graham Brown Cancer Center, University of Louisville, Louisville, Kentucky, USA
hrp0086p1-p600
A Lipid-Based System for the Oral Delivery of Growth Hormone
aInstitute of Pharmacy and Molecular Biotechnology, Heidelberg, Germany; bMedical Center of Childhood and Adolescence, Frankfurt, Germany; cBernina Plus GmbH, München, Germany
hrp0086p1-p601
Prediction of First Year Response to Growth Hormone Treatment in Neural Network Models
aDepartment of Automatics and Biomedical Engineering, AGH University of Science and Technology, Cracow, Poland; bDepartment of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital – Research Institute, Lodz, Poland; cDepartment of Pediatric Endocrinology, Medical University of Lodz, Lodz, Poland
hrp0086p1-p602
Pediatric Phase 2 Data Demonstrate that TransCon hGH Has an Anti-hGH Immunogenic Profile that is Comparable to Daily hGH
aAscendis Pharma A/S, Hellerup, Denmark; bDivision of Endocrinologie Pediatrique – Hopital Mere-Enfant, University Claude Bernard Lyon1, Lyon, France
hrp0086p1-p603
The Exon3-Deleted Growth Hormone Receptor Gene Polymorphism (d3-GHR) is Associated with Increased Spontaneous Growth and Impaired Insulin Sensitivity in Prepubertal Short SGA Children (NESGAS)
aDepartment of Growth and Reproduction, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; bDepartment of Padiatrics, University of Cambridge, Cambridge, UK; cDepartment of Endocrinology, Birmingham Children’s Hospital, Birmingham, UK; dDepartment of Endocrinology, Royal Hospital for Sick Children, Glasgow, UK; eDepartment of Clinical Sciences, University of Lund, Malmö, Sweden; fPediatric Endocrinology Unit, Karolinska Institutet and University Hospital, Stockholm, Sweden; gDepartment of Pediatrics, The National Children’s Hospital, University of Dublin, Dublin, Ireland
hrp0086p1-p604
A New Case of Intragenic Deletion in IGF1R with Very Mild Phenotype
Dipartimento della Donna, del Bambino e di Chirurigia Generale e Specialistica, Seconda Università degli Studi di Napoli, Naples, Italy
hrp0086p1-p605
The Role of IGF-1R Gene Polymorphisms with Regard to Susceptibility to Idiopathic Short Stature Risk in the Chinese Population of Jiangxi Area
aDepartment of Endocrinology, Genetics and Metabolism, Jiangxi Provincial Children’s Hospital, Nanchang, China; bDepartment of Pediatrics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; cKey Laboratory of Health and Disease Genomics, Chinese National Human Genome Center at Shanghai, Shanghai, China
hrp0086p1-p606
Pubertal Height Gain in Females with Isolated Growth Hormone Deficiency Treated with rhGH Alone or in Combination with GnRHan
aFirst Department of Pediatrics, School of Medicine, “Aghia Sophia” Children’s Hospital, University of Athens, Athens, Greece; bInstitute of Preventive Medicine, Environmental and Occupational Health – Prolepsis, Athens, Greece
hrp0086p1-p608
Cognitive Abilities and Academic Achievement Among Youths with Short Stature Receiving Growth Hormone Therapy
aDepartment of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA; bChild Health Evaluation And Research Unit, University of Michigan, Ann Arbor, Michigan, USA
hrp0086p1-p609
IGFALS Gene Deletion in a Family with Short Stature
aPediatric Endocrinology Department, Diyarbakir Child Health Hospital, Diyarbakir, Turkey; bPediatric Endocrinology and Growth Department, Leiden University Medical Center, Leiden, The Netherlands
hrp0086p1-p611
Glucose Dysregulation in Children with Growth Hormone Deficiency (GHD), Turner Syndrome (TS) or Born Small for Gestational Age (SGA) Treated with GH: A Report from the NordiNet International Outcome Study (IOS)
aUniversity of Ljubljana, Ljubljana, Slovenia; bUniversität des Saarlandes, Homburg/Saar, Germany; cNovo Nordisk A/S, Søborg, Denmark; dNovo Nordisk Health Care AG, Zurich, Switzerland; eUniversity of Southern Denmark, Odense, Denmark
hrp0086p1-p613
Serum [alpha]-Klotho Levels are not Informative for the Evaluation of GH Secretion in Short Children
aPaediatrics Department, Ain Shams University, Cairo, Egypt; bPaediatric and Adolescent Unit, Internal Medicine and Therapeutics Department, University of Pavia, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; cMarienklinik, Bolzano, Italy; dLaboratory of Clinical Chemistry Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; eIRCCS Fondazione Salvatore Maugeri, Pavia, Italy; fOspedale Regionale di Bolzano, Bolzano, Italy
hrp0086p1-p614
Serum IGF-I, IGFBP-3 and Als Concentrations and Physical Performance in Young Swimers During a Training Season
aSchool of Medicine of Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil; bSchool of Physical Education and Sports of Ribeirao Preto, Ribeirao Preto, Sao Paulo, Brazil
hrp0086p1-p616
Design and Clinical Development of TransCon Growth Hormone for Growth Hormone Deficiency (GHD)
aAscendis Pharma A/S, Hellerup, Denmark; bAscendis Pharma, Inc., Palo Alto, USA; cAscendis Pharma GmbH, Heidelberg, Germany
hrp0086p1-p618
Efficacy of Growth Hormone Treatment in Patients with Type 1 Diabetes Mellitus and Growth Hormone Deficiency
aDepartment of Pediatrics, Klinikum Wels-Grieskirchen, Wels, Austria; bDepartment of Pediatrics, Technical University München, Munich, Germany; cPfizer Health AB, Sollentuna, Sweden; dLiggins Institute, University of Auckland, Auckland, New Zealand; eDepartment of Paediatrics, University of Cambridge, Cambridge, UK; fPfizer. Inc., Endocrine Care, New York, USA; gInstitute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany
hrp0086p1-p620
Final Height after Growth Hormone Treatment in Children with Chronic Renal Failure
aUnit of Endocrinology and Diabetes, Bambino Gesù Children’s Hospital, Rome, Italy; bDepartment of Biomedical Sciences and Human Oncology, Pediatrics Unit, University of Bari A. Moro, Bari, Italy; cDivision of Nephrology and Dialysis, Bambino Gesù Children’s Hospital, Rome, Italy
hrp0086p1-p621
Major Plasma Carotenoids Levels in Growth Hormone Deficient Children
aEndocrinology Research Centre, Moscow, Russia; bMoscow State University, Faculty of Biology, Moscow, Russia
hrp0086p1-p622
Autosomal Dominant Growth Hormone Deficiency due to a Novel Mutation in the gh1 Gene
aChildren’s Hospitals and Clinics of Minnesota, Minneapolis, Minnesota, USA; bFulgent Diagnostics, Temple City, California, USA; cUniversity of Minnesota Masonic Children’s Hospital, Minneapolis, Minnesota, USA
hrp0086p1-p623
A Novel GH1 Mutation in a Family with Autosomal-Dominant Type II Isolated Growth Hormone Deficiency
Ankara Pediatric Hematology and Oncology Training and Research Hospital, Pediatric Endocrinology, Ankara, Turkey
hrp0086p1-p624
Significance of IGF-I Generation Test in Diagnosing Primary and Non-Primary IGF-I Deficiency - Clinical Considerations
aDepartment of Endocrinology and Metabolic Diseases, Polish Mother’s Memorial Hospital - Research Institute, Lodz, Poland; bDepartment of Automatics and Biomedical Engineering, AGH University of Science and Technology, Cracow, Poland; cDepartment of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland; dDepartment of Pediatric Endocrinology, Medical University of Lodz, Lodz, Poland
hrp0086p1-p626
Change of Growth Pattern and Thickness of Epiphyseal Plate in Female Rats According to Injected Estrogen Dosage
aPediatrics, Hyundae General Hospital, Gyeonggi-do, Republic of Korea; bPediatrics, Kyung Hee University Hospital, Seoul, Republic of Korea; cAnatomic Pathology, Kyung Hee University Hospital, Seoul, Republic of Korea; dPediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea
hrp0086p1-p627
Height Gain and Safety Outcomes in Growth Hormone (GH)-Treated Girls and Boys with Idiopathic Short Stature (ISS): Experience from the Prospective GeNeSIS Observational Study
aEli Lilly and Company, Windlesham, UK; bSydney Children’s Hospital, Randwick, Australia; cEli Lilly and Company, Indianapolis, USA; dUniversity of Montreal and CHU Ste-Justine, Montreal, Canada; eThomas Jefferson University, Philadelphia, Pennsylvania, USA; fOregon Health Sciences University, Portland, Oregon, USA; gCutler Consultancy LLC, Deltaville, Virginia, USA; hUniversity Children’s Hospital, Univeristy of Giessen, Giessen, Germany
hrp0086p1-p628
Treatment of Resistant Paediatric Somatotropinomas due to AIP Mutation with Pegvisomant
aRoyal Children’s Hospital, Melbourne, Victoria, Australia; bMurdoch Children’s Research Institute, Melbourne, Victoria, Australia
hrp0086p1-p629
GH-Pattern with High Trophs are Often Found after Daily sc rhGH-Injection in Children
aInstitute of Clinical Science/Pediatrics, Umea University, Umea SE-90185, Sweden; bDepartmen of Physiology/Endocrinology, Institute of Neurosciences and Physiology, Salhgrenska Academy, University of Gothenburg, Gothenburg SE-40530, Sweden
hrp0086p1-p630
Are the GH Treatment Doses in Use within Secretion Rates of Healthy Children?
aInstitute of Clinical Science/Pediatrics, Umeå Univesity, Umea SE-90185, Sweden; bDepartment of Physiology/Endocrinology, Institute of Neurosciences and Physiology, The Sahlgrenska Academy at University of Gothenburg, Gothenburg SE-40530, Sweden
hrp0086p1-p631
The Influence of Growth Hormone Treatment on Fat-free Mass in Prepubertal Children with Kabuki Syndrome
aMaastricht University Medical Center, Maastricht, The Netherlands; bZuyderland Medical Center, Heerlen, The Netherlands
hrp0086p1-p632
Four-Year Results from PATRO Children, a Multi-Centre, Non-Interventional Study of the Long-Term Safety and Efficacy of Omnitrope® in Children Requiring Growth Hormone Treatment
aUniversity of Leipzig Medical School, Leipzig, Germany; bRoyal Alexandra Children’s Hospital, Brighton, UK; cKarolinska University Hospital, Stockholm, Sweden; dUmea University, Umea, Sweden; eSandoz International, Holzkirchen, Germany; fUniversity Children’s Hospital, Ljubljana, Slovenia; g25 rue Boudet, Bordeaux, France
hrp0086p1-p634
Glucagon vs Clonidine Stimulation for Testing Growth Hormone Secretion in Children and Adolescents: Which is Better?
Schneider Children’s Medical Center-Institute for Endocrinology and Diabetes, Petah Tikva, Israel
hrp0086p1-p635
Spanish ECOS Study Analysis: Socioeconomic Data, Adherence and Growth Outcomes with Case Studies
aHospital General Universitario Gregorio Marañón, Madrid, Spain; bHospital Universitario Araba, Araba/Alava, Spain; cHospital Universitario Príncipe de Asturias, Madrid, Spain; dCentro Nuevas Tecnologias, Sevilla, Spain; eRegional Clinical Operations, Merck S.L., Madrid, Spain; fMedical Affairs, Merck S.L., Madrid, Spain; gGlobal Medical, Merck KGaA, Darmstadt, Germany
hrp0086p1-p639
Analysis of Correlation between Stem Cells (CD133+/CD45+ and CD133+/CD45−) and Anthropometric Parameters of Children with Growth Hormone/Primary Insulin-Like Growth Factor 1 Deficiency
aDiabetes with the Cardiology Division, Department of Pediatrics Endocrinology, Medical University in Bialystok, Bialystok, Poland; bDepartment of Regenerative Medicine and Immune Regulation, Medical University in Bialystok, Bialystok, Poland; cDepartment of Hematology Diagnostic, Medical University in Bialystok, Bialystok, Poland
hrp0086p1-p640